Kigtropin — торгова марка синтетично створеної людини,Kigtropin — найкращий соматропін HGH на ринку, найефективніший і найкращий результат, який може отримати людина, kigtropin розроблено. Ми відправляємо замовлення із США, Китай, і я. Ми є дистриб'ютором?kigtropin HGH оптовий продавець? Кігтропін HGH, Будь ласка, придбайте більше kigtropin HGH Китай (Материк) виробників, експортери, постачальники, фабрики, Companies from China .
Kigtropin is a Human Growth Hormone (hGH) Somatropin produced with recombinant DNA technology identical to the body naturally produced HGH.
Growth failure of children due to endogenous growth hormone deficiency (GHD).
У дорослих з дефіцитом гормону росту,KIGTROPIN reduces fat mass,збільшує м'язову масу і покращує енергію,життєвий тонус і суб'єктивне благополуччя. У хворих з сильними опіками,Втрата м’язів, пов’язана зі СНІДом,або проходити серйозні операції,KIGTROPIN promotes wound healing,attenuates the protein-catabolic response and improves whole-body nitrogen condition after operation.
Kigtropin comes as a freeze dried white powder – 10 x 10 IU (3.3 мг) флаконів на коробку. Як і деякі інші, він починався як вигаданий бренд, який став популярним завдяки хорошим відгукам у спільноті бодібілдингу. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 місяців. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 років, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. тому, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
